These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38023118)

  • 1. Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the
    Zhang J; Tang Z; Guo X; Wang Y; Zhou Y; Cai W
    Front Oncol; 2023; 13():1303608. PubMed ID: 38023118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the
    Zhang J; Tang Z; Guo X; Wang Y; Zhou Y; Cai W
    Front Oncol; 2022; 12():933646. PubMed ID: 35992834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
    Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB
    J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer.
    Mu F; Fan B; Li H; Qin W; Wang C; Zou B; Wang L
    Future Oncol; 2023 Jun; 19(19):1367-1378. PubMed ID: 37114967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Efficacy of Albumin-Bound Paclitaxel for Human Lung and Colorectal Cancers through Autophagy Receptor Sequestosome 1 (SQSTM1)/p62-Mediated Nanodrug Delivery and Cancer therapy.
    Lin YW; Lin TT; Chen CH; Wang RH; Lin YH; Tseng TY; Zhuang YJ; Tang SY; Lin YC; Pang JY; Chakravarthy RD; Lin HC; Tzou SC; Chao JI
    ACS Nano; 2023 Oct; 17(19):19033-19051. PubMed ID: 37737568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases.
    Tanei T; Leonard F; Liu X; Alexander JF; Saito Y; Ferrari M; Godin B; Yokoi K
    Cancer Res; 2016 Jan; 76(2):429-39. PubMed ID: 26744528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer.
    Okuno K; Garg R; Yuan YC; Tokunaga M; Kinugasa Y; Goel A
    Front Oncol; 2022; 12():952180. PubMed ID: 35847926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study.
    Oi H; Matsuda T; Kimura T; Morise M; Yamano Y; Yokoyama T; Kataoka K; Kondoh Y
    Medicine (Baltimore); 2022 Feb; 101(6):e28863. PubMed ID: 35147134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
    Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.
    Cheng X; Yang F; Wang Y; Nie W; Mahendra Upadhyay A; Zhang M; Wang Q; Yan Z
    Can J Gastroenterol Hepatol; 2022; 2022():6015877. PubMed ID: 35719323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models.
    Chen H; Huang S; Wang H; Chen X; Zhang H; Xu Y; Fan W; Pan Y; Wen Q; Lin Z; Wang X; Gu Y; Ding B; Chen J; Wu X
    Drug Deliv; 2021 Dec; 28(1):1067-1079. PubMed ID: 34109887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
    Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
    Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
    Matsui Y; Yamada T; Morimoto K; Katayama Y; Hiranuma O; Shiotsu S; Tamiya N; Takeda T; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
    Anticancer Res; 2022 Oct; 42(10):4921-4928. PubMed ID: 36191970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.